EUVIMEDEUVIMED entdecken
Crossref

Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling

Guanqing Zhang, Xinhao Wang, Yue Wang, Huan Liu, Qiqiang Xie, Xin Li, Maolei Xu, Ling Zhou iD

Journal of Pharmacy and Pharmacology · 04.11.2026 · 78 (11)

DOI: 10.1093/jpp/rgag139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 10.11.2026. Verfasst von Guanqing Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, S…. Hauptthemen laut MEDLINE: Cisplatin, STAT3 Transcription Factor, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation, State Key Laboratory of Natural and Biomimetic Drugs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Cisplatin resistance in non-small cell lung cancer (NSCLC) is closely associated with inflammation. This study investigates whether tiliroside, a bioactive flavonoid exhibiting potent anti-inflammatory properties, can sensitize both NSCLC and its cisplatin-resistant variants to cisplatin treatment.

Methods

The reversal of cisplatin resistance and synergistic interactions between tiliroside and cisplatin were evaluated in vitro using cell proliferation, apoptosis, and comet assays, and in vivo via mouse xenograft models. Underlying mechanisms were elucidated through transcriptomic analysis and rescue experiments, while direct target engagement was characterized using molecular docking, cellular thermal shift assays, and biolayer interferometry. Key findings Tiliroside synergistically reversed both intrinsic and acquired cisplatin resistance in vitro and in vivo. Transcriptomic analysis revealed upregulated IL-17A and IL-17RA expression, alongside activated IL-17 signaling, in cisplatin-resistant A549 cells. Target investigations demonstrated that tiliroside directly binds to IL-17RA, downregulating its expression and subsequently inhibiting the downstream IL-17/JAK2/STAT3 pathway. Furthermore, human recombinant IL-17A and IL-6 counteracted the inhibitory effects of tiliroside on STAT3 activation and its ability to enhance cisplatin sensitivity.

Conclusions

IL-17RA represents a promising clinical target for overcoming cisplatin resistance in NSCLC. Tiliroside could serve as a valuable chemosensitizer by directly targeting IL-17RA to inhibit JAK2/STAT3 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinSTAT3 Transcription FactorCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsJanus Kinase 2FlavonoidsReceptors, Interleukin-17HumansAnimalsSignal TransductionDown-RegulationInterleukin-17MiceA549 CellsAntineoplastic AgentsCell ProliferationXenograft Model Antitumor AssaysApoptosisMice, NudeMolecular Docking SimulationCell Line, TumorDrug Synergism

Stichwörter der Autor:innen

IL-17RAJAK2/STAT3NSCLCcisplatin resistancetiliroside

Substanzen

CisplatinSTAT3 Transcription FactorJanus Kinase 2STAT3 protein, humanJAK2 protein, humanFlavonoidstilirosideInterleukin-17Antineoplastic AgentsReceptors, Interleukin-17

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Shandong Medical and Pharmaceutical University, Yantai Shandong 264003,…
  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100871, PR China.

ORCID-Profile: Ling Zhou

Förderung

  • National Natural Science Foundation of China
  • Shandong Provincial Natural Science Foundation
  • State Key Laboratory of Natural and Biomimetic Drugs
  • Projects of medical and health technology development program in Shandong province

Zitieren

APA

Zhang, G., Wang, X., Wang, Y., Liu, H., Xie, Q., Li, X., Xu, M., & Zhou, L. (2026). Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling. Journal of Pharmacy and Pharmacology, 78(11). https://doi.org/10.1093/jpp/rgag139

Vancouver

Zhang G, Wang X, Wang Y, Liu H, Xie Q, Li X, et al. Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling. Journal of Pharmacy and Pharmacology. 2026;78(11). doi:10.1093/jpp/rgag139

BibTeX
@article{Zhang2026,
  author = {Zhang, Guanqing and Wang, Xinhao and Wang, Yue and Liu, Huan and Xie, Qiqiang and Li, Xin and Xu, Maolei and Zhou, Ling},
  title = {Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {11},
  doi = {10.1093/jpp/rgag139}
}
Kostenlos starten →